Journal Home > Volume 18 , Issue 5
Tsinghua Science and Technology 2013, 18(5): 441-445 https://doi.org/10.1109/TST.2013.6616517
Open Access | Issue | Published: 03 October 2013

Early Diagnostic Value of Circulating MiRNA-21 in Lung Cancer: A Meta-Analysis

Show Author's Information Chang Liu,  Youping Deng( ),  Leilei Wang,  Yong Mei,  Rui Zhang
Department of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China
Department of Systems Biology and Bioinformatics, Wuhan University of Science and Technology, Wuhan 430065, China
Keywords:
microRNA, early diagnosis, lung cancer, meta-analysis
Cite this article:
Liu C, Deng Y, Wang L, et al. Early Diagnostic Value of Circulating MiRNA-21 in Lung Cancer: A Meta-Analysis. Tsinghua Science and Technology, 2013, 18(5): 441-445. https://doi.org/10.1109/TST.2013.6616517
Download citation
EndNote(RIS)
BibTeX

487

Views

14

Downloads

Citations

6

Crossref

N/A

WoS

7

Scopus

0

CSCD

Abstract Full text About this article

To evaluate the early diagnostic value of circulating miRNA-21 in diagnosis of lung cancer, databases such as Wan Fang, VIP, PubMed, and Elsevier were systematically searched from 2005 to 2013 to collect relevant references in which the diagnostic value had been evaluated. The statistics were consolidated and the qualities of the studies were classified. The data were analyzed using Meta Disc1.4 software. The diagnostic value of circulating miRNA-21 in lung cancer was assessed by pooling sensitivity, specificity, the likelihood ratio, and the Summary Receiver Operating Characteristic (SROC) curve. Publication biases of the studies involved were analyzed using Stata 11.0 software. A total of 143 papers were collected of which 8 were included, which contained 600 cases and 440 controls. A heterogeneity test proved the existence of homogeneity in this study. Upon analysis using random effects models, the weighted sensitivity was 0.68, the specificity 0.77, the positive likelihood ratio 2.84, the negative likelihood ratio 0.40, and the SROC Area Under the Curve (AUC) was 0.8133. Further analysis by subgroup showed that the 5 indicators mentioned above were 0.72, 0.84, 4.50, 0.27, and 0.8987, respectively, for the serum group and 0.63, 0.70, 1.95, 0.53, and 0.7318, respectively, for the plasma group. We conclude that circulating miRNA-21 can be regarded a valuable reference in diagnosis of lung cancer. This research showed that in lung cancer the early diagnostic value of miRNA-21 in serum was better than that in plasma.


menu
Abstract
Full text
Outline
About this article

Early Diagnostic Value of Circulating MiRNA-21 in Lung Cancer: A Meta-Analysis

Show Author's information Chang Liu, Youping Deng( ), Leilei Wang, Yong Mei, Rui Zhang
Department of Medicine, Wuhan University of Science and Technology, Wuhan 430065, China
Department of Systems Biology and Bioinformatics, Wuhan University of Science and Technology, Wuhan 430065, China

Abstract

To evaluate the early diagnostic value of circulating miRNA-21 in diagnosis of lung cancer, databases such as Wan Fang, VIP, PubMed, and Elsevier were systematically searched from 2005 to 2013 to collect relevant references in which the diagnostic value had been evaluated. The statistics were consolidated and the qualities of the studies were classified. The data were analyzed using Meta Disc1.4 software. The diagnostic value of circulating miRNA-21 in lung cancer was assessed by pooling sensitivity, specificity, the likelihood ratio, and the Summary Receiver Operating Characteristic (SROC) curve. Publication biases of the studies involved were analyzed using Stata 11.0 software. A total of 143 papers were collected of which 8 were included, which contained 600 cases and 440 controls. A heterogeneity test proved the existence of homogeneity in this study. Upon analysis using random effects models, the weighted sensitivity was 0.68, the specificity 0.77, the positive likelihood ratio 2.84, the negative likelihood ratio 0.40, and the SROC Area Under the Curve (AUC) was 0.8133. Further analysis by subgroup showed that the 5 indicators mentioned above were 0.72, 0.84, 4.50, 0.27, and 0.8987, respectively, for the serum group and 0.63, 0.70, 1.95, 0.53, and 0.7318, respectively, for the plasma group. We conclude that circulating miRNA-21 can be regarded a valuable reference in diagnosis of lung cancer. This research showed that in lung cancer the early diagnostic value of miRNA-21 in serum was better than that in plasma.

Keywords: microRNA, early diagnosis, lung cancer, meta-analysis

References(18)

[1]
A.Jemal, F.Bray, M. M.Center, J.Ferlay, E.Ward, and D.Forman, Global cancer statistics, CA Cancer J. Clin., vol. 61, no. 2, pp. 69-90, 2011.
DOI Google Scholar
[2]
E. M.Toloza, L.Harpole, and D.C.McCrory, Noninvasive staging of non-small cell lung cancer: A review of the current evidence, Chest., vol. 123, no. Suppl 1, pp. 137S-146S, 2003.
DOI Google Scholar
[3]
C. I.Henschke, D. F.Yankelevitz, D. M.Libby, M. W.Pasmantier, J. P.Smith, and O. S.Miettinen, Survival of patients with stage I lung cancer detected on CT screening, N. Engl. J. Med., vol. 355, no. 17, pp. 1763-1771, 2006.
DOI Google Scholar
[4]
V.Ambros, The functions of animal microRNAs, Nature, vol. 431, no. 7006, pp. 350-355, 2004.
DOI Google Scholar
[5]
M.Lagos-Quintana, R.Rauhut, W.Lendeckel, and T.Tuschl, Identification of novel genes coding for small expressed RNAs, Science, vol. 294, no. 5543, pp. 853-858, 2001.
DOI Google Scholar
[6]
Y.Huang, X. J.Shen, Q.Zou, S. P.Wang, S. M.Tang, and G. Z.Zhang, Biological functions of microRNAs: A review, J. Physiol. Biochem., vol. 67, no. 1, pp. 129-139, 2011.
DOI Google Scholar
[7]
J. L.Wang, Evidenced Based Medicine. Beijing, China: People’s Medical Publishing House, 2001.
[8]
Y.Li, W.Li, Q.Ouyang, S.Hu, and J.Tang, Detection of lung cancer with blood microRNA-21 expression levels in Chinese population, Oncol. Lett., vol. 2, no. 5, pp. 991-994, 2011.
Google Scholar
[9]
J.Shen, N. W.Todd, H.Zhang, L.Yu, X.Lingxiao, Y.Mei, M.Guarnera, J.Liao, A.Chou, C. L.Lu, et al., Plasma microRNAs as potential biomarkers for non-small-cell lung cancer, Lab. Invest., vol. 91, no. 4, pp. 579-587, 2011.
DOI Google Scholar
[10]
J.Shen, Z.Liu, N. W.Todd, H.Zhang, J.Liao, L.Yu, M. A.Guarnera, R.Li, L.Cai, M.Zhan, et al., Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers, BMC Cancer, vol. 11, p. 374, 2011.
DOI Google Scholar
[11]
J.Wei, W.Gao, C. J.Zhu, Y. Q.Liu, Z.Mei, T.Cheng, and Y. Q.Shu, Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer, Chin. J. Cancer, vol. 30, no. 6, pp. 407-414, 2011.
DOI Google Scholar
[12]
B.Wangand Q.Zhang, The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors, J. Cancer. Res. Clin. Oncol., vol. 138, no. 10, pp. 1659-1666, 2012.
DOI Google Scholar
[13]
H. B. Le, W. Y.Zhu, D. D.Chen, J. Y.He, Y. Y.Huang, X. G.Liu, and Y. K.Zhang, Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients, Med. Oncol., vol. 29, no. 5, pp. 3190-3197, 2012.
DOI Google Scholar
[14]
D.Tang, Y.Shen, M.Wang, R.Yang, Z.Wang, A.Sui, W.Jiao, and Y.Wang, Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer, http://www.ncbi.nlm.nih.gov/pubmed/23462458, 2013.
DOI
[15]
A. A.Abd-El-Fattah, N. A.Sadik, O. G.Shaker, and M. L.Aboulftouh, Differential microRNAs expression in serum of patients with lung cancer, Pulmonary Tuberculosis, and Pneumonia, http://www.ncbi.nlm.nih.gov/pubmed/23559272, 2013.
DOI
[16]
H.Zhang, The study on plasma miR-145, miR-20a, miR-21, and miR-223 as non-invasive biomarkers for early-stage non-small cell lung cancer, Ph. D. Dissertation, Suzhou University, China, 2012.
[17]
R.Jaeschke, G. H.Guyatt, and D. L.Sackett, Users’ guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group, JAMA, vol. 271, no. 9, pp.703-707, 1994.
DOI Google Scholar
[18]
X.Chen, Z.Hu, W.Wang, Y.Ba, L.Ma, C.Zhang, C.Wang, Z.Ren, Y.Zhao, S.Wu, et al., Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis, Int. J. Cancer, vol. 130, no. 7, pp. 1620-1628, 2012.
DOI Google Scholar
Publication history
Copyright
Rights and permissions

Publication history

Received: 06 August 2013
Accepted: 19 August 2013
Published: 03 October 2013
Issue date: October 2013

Copyright

© The author(s) 2013

Rights and permissions

Return